(Q42671091)

4 November 2017

Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure (English)

1 reference

4 November 2017

0 references

Marc A Silver

1

1 reference

4 November 2017

Darlene P Horton

series ordinal

2

1 reference

4 November 2017

Jalal K Ghali

series ordinal

3

1 reference

4 November 2017

Uri Elkayam

series ordinal

4

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

Journal of the American College of Cardiology

4 November 2017

1 reference

4 November 2017

39

1 reference

4 November 2017

5

1 reference

4 November 2017

798-803

1 reference

Cost-effectiveness analysis in clinical practice: the case of heart failure

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901818-6

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901818-6

7 January 2021

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901818-6

7 January 2021

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901818-6

7 January 2021

Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901818-6

7 January 2021

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901818-6

7 January 2021

Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901818-6

7 January 2021

Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901818-6

7 January 2021

10.1016/S0735-1097(01)01818-6

Identifiers

DOI

1 reference

4 November 2017

1 reference